New Prostate Cancer Treatment Offers Precision (and Fewer Side Effects)

Using ultrasound waves, an individualized approach to treating prostate cancer might offer several big benefits. A Michigan Medicine urologist explains.

7:00 AM

Author | Kevin Joy

Arvin George, M.D.

A new treatment option for some prostate cancer patients could radically change how doctors combat the disease — helping recipients bounce back faster and without side effects such as urinary incontinence and loss of erectile function.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Known as high-intensity focused ultrasound (HIFU), the technology deploys ultrasound waves via the rectum to target cancerous tissue.

That marks a shift from current prostate cancer treatment options in the United States: active surveillance to monitor for development of aggressive cancer or radiation therapy and prostatectomy (surgery that involves full removal of the prostate).

HIFU, by comparison, is "a middle ground," says Arvin George, M.D., an assistant professor of urology at Michigan Medicine.

"It's a minimally invasive procedure that can provide cancer control and that can delay, potentially indefinitely, the need for surgery or radiation."

Another upside: It's precise.

Initially determined using an MRI-guided biopsy, the targeted zone absorbs energy from the HIFU waves, converting it into heat. Bubbles form within cells during the two- to four-hour treatment and cause the cells to break up, thus destroying the cancerous tissue.

Patients feel little pain afterward and are monitored periodically to ensure the cancer hasn't returned.

Performed elsewhere, mostly in Europe, since the 1990s, the Food and Drug Administration approved HIFU for prostate ablation in 2015.

It became available at the University of Michigan Comprehensive Cancer Center in September.

Michigan Medicine urologists Jeffrey Montgomery, M.D., left, and Arvin George, M.D.

What to know about high-intensity focused ultrasound

George, in his own words, spoke more about the technology and its potential:

How it works: The HIFU procedure essentially uses ultrasound waves directed to a specific area of the prostate. Focused on that point, it generates heat to destroy the affected tissue. Bubbles form and break up the affected tissue. Your body eventually absorbs the treated area and breaks it down.

Who might be a candidate: We don't necessarily treat high-risk prostate cancer with HIFU. We usually look for patients with low- to intermediate-risk cancers. The goal is to avoid affecting the nerves that run just behind the prostate on the left and right side, so the ideal patient is someone whose cancer is not close to the nerves or other vital structures.

Why it's effective: It's very precise. You can plan your treatments around a very small area you want to treat. This is a lot more patient-specific. We can treat two groups: those with a very specific spot of cancer and those whose cancer is confined to one side. We can safely treat one-fourth or one-half or three-quarters of the prostate.

SEE ALSO: How Technology Is Making Prostate Cancer Biopsies More Precise

How it affects quality of life: Compared to major surgery or radiation, the side effects — risks of incontinence and losing erectile function — are much lower. HIFU allows men to avoid or live without such side effects for a period of time if they are ever to require whole gland treatment in the future.

How patients recover: Done under general anesthesia, this is a well-tolerated outpatient procedure. It doesn't require hormone therapy or radiation. Conventional treatments result in a lot of downtime; radiation requires about 40 treatments. With surgery, you're out of work for a few weeks with potentially long-lasting side effects. Here, patients go home the same day.

What it costs: HIFU costs about $20,000 to $30,000. Recently, a Medicare C-code was introduced that would cover facility costs in our region — which will likely decrease the out of pocket cost to the patient to anywhere from $8,000 to $11,000. As we get more available data, I think there's a stronger path for approval [in other regions]. You need to be able to prove the treatment is effective.

What questions remain: We don't yet have long-term data. It may not be as effective as surgery or radiation in the long term. However, some men don't need such invasive treatments. There is a risk — about 20 to 30 percent — that it can come back. But you can treat a patient again with focal therapy if needed, and you don't lose the option of doing surgery or radiation.

For more information about HIFU for prostate cancer, call U-M's Cancer AnswerLine™. Call 1-800-865-1125 from anywhere in the country to connect with an experienced oncology nurse.


More Articles About: Cancer Care Prostate Cancer Rogel Cancer Center Emerging Technologies Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories cancer cell blue yellow
Health Lab
Widening inequality seen where cancer clinical trials are available
The availability of clinical trials of new treatments for cancer varies greatly by geography, and a new study shows more socially vulnerable areas have far fewer.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
If they don't give up, how can I give up?
Today on The Fundamentals is Dr. Maria Castro, the R.C. Schneider collegiate professor of neurosurgery, and a professor of cell and developmental biology at the University of Michigan Medical School. Her research program aims to develop immunotherapies for primary and metastatic brain cancer, studying basic immune biology mechanisms leading to clinical implementation. She has been inducted into the American Association for the Advancement of Sciences, the Latin American Academy of Sciences, and the American Institute for Medical and Biological Engineering College of Fellows. She has won numerous awards for her contributions to basic science and cancer research and is a diversity ambassador for the Cancer Biology Graduate Training Program. You can learn more about Dr. Castro here, and you can follow her @castro2355_mg, the Rogel Cancer Center @UMRogelCancer, the department of neurosurgery @umichneuro, Michigan Neurscience Institute @UM_MNI and the department of cell and developmental biology @UMCDB on X
Illustration of hand holding list, with pill bottle in opposite and and small pic of doctor talking to patient
Health Lab
New urine-based test detects high grade prostate cancer, helping men avoid unnecessary biopsies
A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.
Illustration of hand holding a smartphone with green background
Health Lab
Medicare pays for message-based e-visits. Are older adults using them?
Telehealth study of patient portal e-visits by Medicare participants shows few had an interaction for which their provider billed them.
Blue image of a microscopic helix strand
Health Lab
Researchers discover urine based test to detect head and neck cancer
At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests
Spilled pills next to a stethoscope and pile of cash
Health Lab
Drug pricing program improved prostate cancer treatment adherence
Socially vulnerable patients were more likely to stick with oral medications when treated at a hospital participating in 340B program, suggesting these hospitals may have more resources to help patients.